Trial Profile
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Carglumic acid (Primary)
- Indications Hyperammonaemia
- Focus Therapeutic Use
- 13 Feb 2020 Planned End Date changed from 1 Jul 2018 to 30 Jun 2020.
- 13 Feb 2020 Status changed from completed to active, no longer recruiting.
- 01 May 2018 Status changed from recruiting to completed.